Obstetrics & Gynecology, Gynecologic Oncology · Cincinnati, OH
NPI
1023273687
Since 2008
Specialty
Obstetrics & Gynecology, Gynecologic Oncology
Code 207VX0201X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
601 Ivy Gtwy Ste 1100
Cincinnati, OH, 45245
Phone (513) 751-2273
Groups this clinician bills Medicare through
Medicare paid, 2024
$349K
14,292 services
Medicare patients, 2024
143
Average age 73
Drug cost, 2024
$535K
223 prescriptions
Company payments, 2025
$480
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ajit Gubbi was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 162 times for 92 patients. In total Ajit Gubbi billed 14,292 services in 100 codes, and Medicare paid $349K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-22.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 162 | 92 | $11.85 | $1,920 |
| 99459 Office/Outpatient Services | Office | 137 | 83 | $15.35 | $2,103 |
| 80053 Clinical Chemistry | Office | 131 | 62 | $10.35 | $1,356 |
| 85025 Blood Count | Office | 131 | 61 | $7.61 | $997 |
| 99214 Office E&M - Established | Office | 121 | 75 | $85.28 | $10K |
| 86304 Immunoassay | Office | 93 | 40 | $20.39 | $1,896 |
| 99215 Office E&M - Established | Office | 86 | 45 | $126.50 | $11K |
| 99205 Office E&M - New | Office | 41 | 41 | $146.37 | $6,001 |
| 96413 Chemotherapy Administration | Office | 39 | 11 | $93.04 | $3,629 |
| 99213 Office E&M - Established | Office | 16 | 16 | $33.96 | $543 |
| 58571 Other Organ Systems | Facility | 14 | 14 | $690.45 | $9,666 |
By year: 2022 $59K for 4,177 services; 2023 $166K for 18,116 services; 2024 $349K for 14,292 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80053 Clinical Chemistry | 131 | 62 | $10.35 | $1,356 |
| 85025 Blood Count | 131 | 61 | $7.61 | $997 |
| 86304 Immunoassay | 93 | 40 | $20.39 | $1,896 |
Medicare prescription drug claims, 2024
In 2024, the drug Ajit Gubbi prescribed most often to Medicare patients was Dexamethasone, with 31 prescriptions and refills. In total Ajit Gubbi wrote 223 Medicare prescriptions that cost $535K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dexamethasone Generic | 31 | 31 | 14 | $228 |
| Ondansetron Hcl Generic | 28 | 28 | 24 | $682 |
| Oxycodone Hcl Generic | 23 | 23 | 22 | $44.8 |
| Olanzapine Generic | 19 | 19 | 15 | $135 |
| Rubraca Rucaparib Camsylate | 13 | 13 | Under 11 | $240K |
Brand drugs: 44 claims; generic drugs: 179 claims; opioid claims: 26.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ajit Gubbi $480 ($480 in general payments such as food, travel and fees) from 14 companies. The largest payer was Merck Sharp & Dohme LLC with $143.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 6 | $143 |
| Janssen Biotech, Inc. JNJ | 3 | $54.52 |
| Eisai Inc. 4523.T | 2 | $37.87 |
| Rigel Pharmaceuticals, Inc. RIGL | 2 | $35.27 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $28.26 |
| Abbvie Inc. ABBV | 1 | $27.16 |
| Aveo Pharmaceuticals, Inc. | 1 | $26 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $23.38 |
| Gilead Sciences, Inc. GILD | 1 | $20.91 |
| Caris MPI, Inc. | 1 | $20.52 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.